| 1 |
Qin B, Wang J, Yang Z, et al. Epidemiology of primary sjögren's syndrome: a systematic review and meta-analysis [J]. Ann Rheum Dis, 2015, 74(11): 1983-1989.
|
| 2 |
Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjögren's syndrome [J]. Rheumatology (Oxford), 2019.
|
| 3 |
Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase Ⅱ study [J]. Ann Rheum Dis, 2015, 74(3): 526-531.
|
| 4 |
De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study [J]. Rheumatology (Oxford), 2015, 54(12): 2249-2256.
|
| 5 |
Dörner T, Posch MG, Li Y, et al. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity [J]. Ann Rheum Dis, 2019, 78(5): 641-647.
|
| 6 |
Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial [J]. Lancet, 2022, 399(10320): 161-171.
|
| 7 |
Alunno A, Carubbi F, Bistoni O, et al. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study [J]. Clin Exp Immunol, 2016, 184(3): 284-292.
|
| 8 |
Ciccia F, Guggino G, Rizzo A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome [J]. Rheumatology (Oxford), 2014, 53(7): 1313-1320.
|
| 9 |
Souza FB, Porfírio GJ, Andriolo BN, et al. Rituximab effectiveness and safety for treating primary Sjögren's syndrome (pSS): systematic review and meta-analysis [J]. PLoS One, 2016, 1(3): e0150749.
|
| 10 |
Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial [J]. Ann Rheum Dis, 2013, 72(1): 146-148.
|
| 11 |
Chevalier K, Belkhir R, Seror R, et al. Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type Ⅱ cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone [J]. Ann Rheum Dis, 2020, 79(9): 1257-1259.
|
| 12 |
Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial [J]. Ann Rheum Dis, 2020.
|
| 13 |
Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase Ⅰ/Ⅱ study [J]. Arthritis Res Ther, 2006, 8(4): R129.
|
| 14 |
Nayar S, Campos J, Smith CG, et al. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome [J]. Ann Rheum Dis, 2019, 78(2): 249-260.
|
| 15 |
Juarez M, Diaz N, Johnston GI, et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome [J]. Rheumatology (Oxford), 2021, 60(3): 1364-1375.
|
| 16 |
Tsuboi H, Matsumoto I, Hagiwara S, et al. Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trial [J]. Mod Rheumatol, 2016, 26(6): 891-899.
|
| 17 |
Machado AC, Dos Santos LC, Fidelix T, et al. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome [J]. Clin Rheumatol, 2020, 39(1): 243-248.
|
| 18 |
Baer AN, Gottenberg JE, St Clair EW, et al. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase Ⅲ, randomised, placebo-controlled trial [J]. Ann Rheum Dis, 2020, 80(3): 339-348.
|
| 19 |
Goules A, Tzioufas AG, Manousakis MN, et al. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases [J]. J Autoimmun, 2006, 26(3): 165-171.
|
| 20 |
Belkhir R, Gestermann N, Koutero M, et al. Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sjögren's syndrome [J]. Scand J Immunol, 2014, 79(1): 37-42.
|
| 21 |
Retamozo S, Sisó-Almirall A, Flores-Chávez A, et al. An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development [J]. Expert Opin Pharmacother, 2021, 22(17): 2359-2371.
|
| 22 |
Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled trial of remicade in primary sjögren's syndrome (TRIPSS) [J]. Arthritis Rheum, 2004, 50(4): 1270-1276.
|
| 23 |
Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial [J]. Arthritis Rheum, 2004, 50(7): 2240-2245.
|
| 24 |
Burge DJ, Eisenman J, Byrnes-Blake K, et al. Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study [J]. Lupus, 2017, 26(8):825-834.
|
| 25 |
van den Hoogen LL, van Laar JM. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome [J]. Best Pract Res Clin Rheumatol, 2020, 34(1): 101485.
|
| 26 |
Price E, Bombardieri M, Kivitz A, et al. Safety and efficacy of filgotinib, lanraplenib, and tirabrutinib in Sjögren's syndrome: randomised, phase 2, double-blind, placebo-controlled study [J]. Rheumatology (Oxford), 2022.
|
| 27 |
Miao M, Hao Z, Guo Y, et al. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren's syndrome [J]. Ann Rheum Dis, 2018, 77(12): 1838-1840.
|
| 28 |
Bikker A, van Woerkom JM, Kruize AA, et al. Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation [J]. Arthritis Rheum, 2010, 62(4): 969-977.
|
| 29 |
Bikker A, Kruize AA, Wenting M, et al. Increased interleukin (IL)-7Rα expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity [J]. Ann Rheum Dis, 2012, 71(6): 1027-1033.
|
| 30 |
Zhou J, Yu Q. Anti-IL-7 receptor-α treatment ameliorates newly established Sjögren's-like exocrinopathy in non-obese diabetic mice [J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(7): 2438-2447.
|
| 31 |
Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions [J]. Cell, 2016, 165(4): 792-800.
|
| 32 |
Khalafalla MG, Woods LT, Camden JM, et al. P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy [J]. J Biol Chem, 2017, 292(40): 16626-16637.
|
| 33 |
Vijmasi T, Chen FY, Chen YT, et al. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease [J]. Mol Vis, 2013, 19: 1957-1965.
|
| 34 |
Norheim KB, Harboe E, Gøransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome-a double blind, randomised clinical trial [J]. PLoS One, 2012, 7(1): e30123.
|
| 35 |
Klinngam W, Janga SR, Lee C, et al. Inhibition of cathepsin S reduces lacrimal gland inflammation and increases tear flow in a mouse model of Sjögren's syndrome [J]. Sci Rep, 2019, 9(1): 9559.
|
| 36 |
Hargreaves P, Daoudlarian D, Theron M, et al. Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome [J]. Arthritis Res Ther, 2019, 21(1): 175.
|